Show
Sort by
-
- Journal Article
- A1
- open access
Rapid onset of action and reduced nasal hyperreactivity : new targets in allergic rhinitis management
-
Emerging roles of innate lymphoid cells in inflammatory diseases : clinical implications
-
EAACI position paper on the standardization of nasal allergen challenges
-
- Journal Article
- A1
- open access
MASK 2017 : ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence
-
Dupilumab improves health-related quality of life and absenteeism in nasal polyposis patients : results from a phase 2a trial
-
- Journal Article
- A1
- open access
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
-
- Journal Article
- A1
- open access
Allergen immunotherapy (AIT) : a prototype of precision medicine
-
Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
-
MP29-02*'s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
-
In vivo diagnosis of allergic diseases-allergen provocation tests
-
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
-
A new intranasal therapy MP29-02* is more effective than current firstline therapy regardless of season, symptom or severity
-
A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis
-
GA(2)LEN sinusitis cohort study: chronic rhinosinusitis -differentiation based on chemokine pattern and IL-5
-
Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma